Drug intelligence / Profile preview

BI-44847

Development stage: Phase 1
Lead developer: Boehringer
Modality: Small Molecules
Administration: Oral

Overview

BI-44847 is an orally active small molecule drug that functions as a sodium/glucose cotransporter 2 (SGLT2) inhibitor. It was developed for the treatment of type 2 diabetes. The drug works by inhibiting SGLT2 in the kidney, thereby reducing glucose reabsorption and promoting urinary glucose excretion to lower blood sugar levels. Originally developed by Ajinomoto and later pursued by Boehringer Ingelheim, BI-44847 reached phase II clinical trials but its development has since been discontinued[1][2][3].

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on BI-44847.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI-44847.

Explore the full profile